Blockchain Registration Transaction Record

Softgel Source Launches 2026 Fast-Turn Program for U.S. Biotech & Pharma

Softgel Source launches a 2026 program with no minimum order and fast turnaround for U.S. biotech and pharma softgel testing, supporting domestic manufacturing growth.

This news matters because it addresses critical challenges in today's manufacturing landscape, where supply chain disruptions and regulatory changes are increasingly common. For businesses in biotech, pharmaceuticals, and supplements, SGS's program offers a practical solution to accelerate product development and testing domestically, reducing reliance on unpredictable offshore sources. This enhances competitiveness, supports U.S. job growth, and ensures faster adaptation to market demands, ultimately benefiting consumers through more reliable and innovative products. In an era of reshoring, such initiatives strengthen economic resilience and innovation capacity.